 Kevin Messacar
Concepts (261)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterovirus Infections | 32 | 2025 | 173 | 10.720 |
Why?
| | Enterovirus D, Human | 21 | 2025 | 87 | 6.610 |
Why?
| | Myelitis | 25 | 2025 | 107 | 6.600 |
Why?
| | Central Nervous System Viral Diseases | 17 | 2025 | 78 | 5.320 |
Why?
| | Neuromuscular Diseases | 17 | 2025 | 146 | 4.940 |
Why?
| | Enterovirus | 14 | 2025 | 82 | 4.590 |
Why?
| | Meningitis | 8 | 2022 | 80 | 3.700 |
Why?
| | Encephalitis | 12 | 2022 | 139 | 3.640 |
Why?
| | Respiratory Tract Infections | 11 | 2025 | 397 | 3.210 |
Why?
| | Disease Outbreaks | 19 | 2026 | 422 | 3.180 |
Why?
| | Parechovirus | 4 | 2025 | 8 | 2.080 |
Why?
| | Anti-Infective Agents | 5 | 2023 | 242 | 2.030 |
Why?
| | Picornaviridae Infections | 4 | 2025 | 50 | 1.910 |
Why?
| | Multiplex Polymerase Chain Reaction | 4 | 2020 | 53 | 1.740 |
Why?
| | Nervous System Diseases | 5 | 2020 | 284 | 1.650 |
Why?
| | Paralysis | 5 | 2020 | 67 | 1.570 |
Why?
| | Hospitals, Pediatric | 5 | 2020 | 556 | 1.440 |
Why?
| | Molecular Diagnostic Techniques | 6 | 2020 | 104 | 1.360 |
Why?
| | Cerebrospinal Fluid | 6 | 2019 | 88 | 1.330 |
Why?
| | Central Nervous System Infections | 2 | 2022 | 35 | 1.310 |
Why?
| | Enterovirus A, Human | 2 | 2022 | 13 | 1.290 |
Why?
| | Child | 50 | 2025 | 22633 | 1.190 |
Why?
| | Antimicrobial Stewardship | 4 | 2023 | 129 | 1.180 |
Why?
| | Epidemiological Monitoring | 4 | 2025 | 69 | 1.150 |
Why?
| | Communicable Diseases | 4 | 2021 | 163 | 1.120 |
Why?
| | Colorado | 21 | 2025 | 4564 | 1.120 |
Why?
| | Anti-Bacterial Agents | 7 | 2025 | 1907 | 1.050 |
Why?
| | Herpesvirus 6, Human | 2 | 2019 | 14 | 1.040 |
Why?
| | Viruses | 4 | 2023 | 165 | 0.900 |
Why?
| | Child, Preschool | 32 | 2025 | 11787 | 0.900 |
Why?
| | Humans | 84 | 2026 | 144759 | 0.800 |
Why?
| | Infant | 26 | 2025 | 10034 | 0.740 |
Why?
| | Respiratory Tract Diseases | 1 | 2024 | 175 | 0.730 |
Why?
| | Influenza, Human | 3 | 2020 | 616 | 0.730 |
Why?
| | Simplexvirus | 2 | 2020 | 82 | 0.730 |
Why?
| | Nervous System Malformations | 1 | 2022 | 47 | 0.690 |
Why?
| | Brain Diseases | 2 | 2020 | 152 | 0.680 |
Why?
| | Sepsis | 2 | 2018 | 640 | 0.670 |
Why?
| | Cranial Nerve Diseases | 3 | 2017 | 43 | 0.670 |
Why?
| | Virus Diseases | 1 | 2022 | 216 | 0.620 |
Why?
| | Acyclovir | 1 | 2020 | 96 | 0.620 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2020 | 50 | 0.610 |
Why?
| | Muscle Hypotonia | 2 | 2020 | 33 | 0.610 |
Why?
| | Exanthema Subitum | 1 | 2019 | 3 | 0.600 |
Why?
| | Drug Utilization | 2 | 2017 | 166 | 0.600 |
Why?
| | Hospitals, Teaching | 1 | 2019 | 119 | 0.590 |
Why?
| | Hepatitis | 1 | 2019 | 43 | 0.590 |
Why?
| | Taenia solium | 1 | 2018 | 5 | 0.580 |
Why?
| | Encephalitis, Viral | 2 | 2020 | 45 | 0.580 |
Why?
| | Neurocysticercosis | 1 | 2018 | 8 | 0.580 |
Why?
| | Meningoencephalitis | 2 | 2019 | 24 | 0.570 |
Why?
| | Gastroenteritis | 1 | 2019 | 63 | 0.560 |
Why?
| | Abdomen | 1 | 2019 | 141 | 0.560 |
Why?
| | Fluoxetine | 1 | 2018 | 54 | 0.550 |
Why?
| | Polymerase Chain Reaction | 6 | 2024 | 1054 | 0.550 |
Why?
| | Bacteriological Techniques | 1 | 2018 | 68 | 0.550 |
Why?
| | Diagnosis, Differential | 6 | 2019 | 1489 | 0.520 |
Why?
| | Metagenomics | 6 | 2023 | 181 | 0.510 |
Why?
| | Vaccines | 1 | 2022 | 389 | 0.500 |
Why?
| | Microbial Sensitivity Tests | 2 | 2025 | 370 | 0.500 |
Why?
| | Retrospective Studies | 18 | 2024 | 17066 | 0.500 |
Why?
| | Bacterial Infections | 1 | 2018 | 246 | 0.480 |
Why?
| | Analgesia, Obstetrical | 1 | 2016 | 32 | 0.480 |
Why?
| | Antiviral Agents | 2 | 2020 | 767 | 0.480 |
Why?
| | Hospitalization | 7 | 2020 | 2433 | 0.480 |
Why?
| | Seizures | 1 | 2020 | 460 | 0.470 |
Why?
| | Analgesia, Epidural | 1 | 2016 | 38 | 0.470 |
Why?
| | Fever | 2 | 2019 | 311 | 0.460 |
Why?
| | Male | 36 | 2025 | 72315 | 0.460 |
Why?
| | Bacteria | 3 | 2023 | 889 | 0.450 |
Why?
| | Health Resources | 1 | 2016 | 129 | 0.430 |
Why?
| | Parotitis | 1 | 2014 | 6 | 0.420 |
Why?
| | Motor Neurons | 1 | 2016 | 234 | 0.410 |
Why?
| | Herpesviridae Infections | 1 | 2015 | 150 | 0.400 |
Why?
| | Respiratory Syncytial Virus, Human | 2 | 2025 | 81 | 0.390 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 865 | 0.390 |
Why?
| | High-Throughput Nucleotide Sequencing | 6 | 2026 | 549 | 0.390 |
Why?
| | Respiratory Syncytial Virus Infections | 2 | 2025 | 136 | 0.380 |
Why?
| | United States | 16 | 2025 | 15966 | 0.370 |
Why?
| | Female | 33 | 2025 | 78271 | 0.370 |
Why?
| | Infant, Newborn | 10 | 2025 | 6429 | 0.360 |
Why?
| | Magnetic Resonance Imaging | 5 | 2020 | 3863 | 0.360 |
Why?
| | Prospective Studies | 7 | 2025 | 7990 | 0.350 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2016 | 428 | 0.350 |
Why?
| | Pediatrics | 1 | 2019 | 1114 | 0.340 |
Why?
| | Referral and Consultation | 1 | 2017 | 851 | 0.330 |
Why?
| | Quality Improvement | 1 | 2019 | 1289 | 0.330 |
Why?
| | Meningitis, Aseptic | 2 | 2020 | 13 | 0.320 |
Why?
| | Seasons | 3 | 2019 | 556 | 0.310 |
Why?
| | Cohort Studies | 6 | 2024 | 5960 | 0.310 |
Why?
| | Brain | 3 | 2018 | 2933 | 0.310 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1185 | 0.290 |
Why?
| | Internship and Residency | 1 | 2019 | 1257 | 0.290 |
Why?
| | Genome, Microbial | 2 | 2019 | 7 | 0.270 |
Why?
| | Adolescent | 17 | 2025 | 22428 | 0.250 |
Why?
| | Molecular Epidemiology | 1 | 2026 | 73 | 0.230 |
Why?
| | Paramyxoviridae Infections | 1 | 2025 | 12 | 0.230 |
Why?
| | Cephalexin | 1 | 2025 | 14 | 0.230 |
Why?
| | Metapneumovirus | 1 | 2025 | 15 | 0.230 |
Why?
| | Rhinovirus | 2 | 2017 | 57 | 0.220 |
Why?
| | Paraplegia | 2 | 2015 | 61 | 0.220 |
Why?
| | Sequence Analysis, DNA | 5 | 2023 | 824 | 0.210 |
Why?
| | Mycoplasma pneumoniae | 1 | 2024 | 53 | 0.210 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2024 | 55 | 0.210 |
Why?
| | Infection Control | 1 | 2026 | 172 | 0.210 |
Why?
| | Pleural Effusion | 1 | 2024 | 60 | 0.210 |
Why?
| | Acute Disease | 4 | 2019 | 1030 | 0.200 |
Why?
| | Cross Infection | 1 | 2026 | 262 | 0.190 |
Why?
| | Adenoviridae Infections | 1 | 2023 | 20 | 0.190 |
Why?
| | Time Factors | 4 | 2018 | 7173 | 0.190 |
Why?
| | Streptococcus pneumoniae | 1 | 2024 | 177 | 0.190 |
Why?
| | Canada | 3 | 2025 | 428 | 0.190 |
Why?
| | Arbovirus Infections | 2 | 2020 | 20 | 0.190 |
Why?
| | Community-Acquired Infections | 1 | 2024 | 174 | 0.190 |
Why?
| | Respiratory System | 1 | 2023 | 149 | 0.180 |
Why?
| | Liver Failure, Acute | 1 | 2023 | 67 | 0.180 |
Why?
| | Pandemics | 4 | 2025 | 1694 | 0.180 |
Why?
| | Fungi | 1 | 2023 | 161 | 0.170 |
Why?
| | Uncertainty | 1 | 2022 | 144 | 0.170 |
Why?
| | Hashimoto Disease | 1 | 2021 | 10 | 0.170 |
Why?
| | Medical Oncology | 1 | 2023 | 332 | 0.160 |
Why?
| | Lung | 1 | 2014 | 4109 | 0.160 |
Why?
| | Brain Abscess | 1 | 2020 | 10 | 0.160 |
Why?
| | Esophageal Perforation | 1 | 2020 | 15 | 0.160 |
Why?
| | Antigens, Viral | 2 | 2019 | 182 | 0.160 |
Why?
| | Meningitis, Viral | 1 | 2020 | 20 | 0.160 |
Why?
| | Esophageal Fistula | 1 | 2020 | 21 | 0.160 |
Why?
| | Genomics | 1 | 2026 | 834 | 0.160 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2020 | 21 | 0.160 |
Why?
| | Muscle Weakness | 1 | 2020 | 92 | 0.160 |
Why?
| | Confusion | 1 | 2020 | 30 | 0.160 |
Why?
| | Immunocompetence | 1 | 2019 | 47 | 0.150 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2019 | 25 | 0.150 |
Why?
| | Myelitis, Transverse | 1 | 2019 | 3 | 0.150 |
Why?
| | Agammaglobulinemia | 1 | 2019 | 36 | 0.150 |
Why?
| | Seroepidemiologic Studies | 1 | 2019 | 172 | 0.150 |
Why?
| | Foreign Bodies | 1 | 2020 | 107 | 0.150 |
Why?
| | Antibodies, Helminth | 1 | 2018 | 6 | 0.150 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2019 | 53 | 0.140 |
Why?
| | Meningitis, Bacterial | 1 | 2019 | 45 | 0.140 |
Why?
| | HIV Infections | 1 | 2014 | 3154 | 0.140 |
Why?
| | Body Fluids | 1 | 2018 | 70 | 0.140 |
Why?
| | Leukocyte Count | 1 | 2018 | 316 | 0.140 |
Why?
| | Arboviruses | 1 | 2017 | 14 | 0.130 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 15 | 0.130 |
Why?
| | Headache | 1 | 2018 | 150 | 0.130 |
Why?
| | Program Development | 1 | 2019 | 370 | 0.130 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 108 | 0.130 |
Why?
| | Refusal to Treat | 1 | 2017 | 16 | 0.130 |
Why?
| | Neuromyelitis Optica | 1 | 2019 | 138 | 0.130 |
Why?
| | Treatment Failure | 1 | 2018 | 365 | 0.130 |
Why?
| | Drug Utilization Review | 1 | 2017 | 61 | 0.130 |
Why?
| | Herpes Simplex | 1 | 2017 | 98 | 0.130 |
Why?
| | RNA | 1 | 2023 | 940 | 0.120 |
Why?
| | Densovirus | 1 | 2016 | 3 | 0.120 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 1985 | 0.120 |
Why?
| | Movement Disorders | 1 | 2017 | 69 | 0.120 |
Why?
| | Muscular Diseases | 1 | 2017 | 108 | 0.120 |
Why?
| | Communicable Disease Control | 1 | 2017 | 86 | 0.120 |
Why?
| | Drug Resistance | 1 | 2017 | 153 | 0.120 |
Why?
| | Prevalence | 2 | 2015 | 2834 | 0.120 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2016 | 18 | 0.120 |
Why?
| | Encephalomyelitis | 1 | 2016 | 14 | 0.120 |
Why?
| | Eosinophilia | 1 | 2018 | 221 | 0.120 |
Why?
| | Electromyography | 2 | 2017 | 415 | 0.120 |
Why?
| | Balamuthia mandrillaris | 1 | 2015 | 4 | 0.120 |
Why?
| | Amebiasis | 1 | 2015 | 5 | 0.120 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1266 | 0.120 |
Why?
| | Genome, Mitochondrial | 1 | 2015 | 29 | 0.120 |
Why?
| | Early Diagnosis | 1 | 2016 | 249 | 0.110 |
Why?
| | Liver Transplantation | 1 | 2023 | 823 | 0.110 |
Why?
| | North America | 1 | 2016 | 310 | 0.110 |
Why?
| | Neoplasms | 2 | 2023 | 2875 | 0.110 |
Why?
| | Program Evaluation | 1 | 2019 | 948 | 0.110 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2016 | 157 | 0.110 |
Why?
| | Biopsy | 1 | 2018 | 1075 | 0.110 |
Why?
| | La Crosse virus | 1 | 2014 | 4 | 0.110 |
Why?
| | Treatment Outcome | 3 | 2019 | 11679 | 0.110 |
Why?
| | Case-Control Studies | 2 | 2020 | 3604 | 0.110 |
Why?
| | Encephalitis, California | 1 | 2014 | 9 | 0.110 |
Why?
| | West Nile Fever | 1 | 2014 | 57 | 0.100 |
Why?
| | Hospitals | 1 | 2019 | 730 | 0.100 |
Why?
| | Kidney | 1 | 2021 | 1495 | 0.100 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 171 | 0.100 |
Why?
| | Adult | 6 | 2023 | 40449 | 0.090 |
Why?
| | Orthomyxoviridae | 1 | 2012 | 40 | 0.090 |
Why?
| | Neuroimaging | 1 | 2014 | 289 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 1137 | 0.090 |
Why?
| | Anti-Retroviral Agents | 1 | 2014 | 250 | 0.090 |
Why?
| | Temperature | 1 | 2015 | 679 | 0.090 |
Why?
| | Models, Theoretical | 2 | 2025 | 582 | 0.090 |
Why?
| | Clinical Competence | 1 | 2019 | 1244 | 0.080 |
Why?
| | Critical Care | 1 | 2017 | 695 | 0.080 |
Why?
| | Population Surveillance | 1 | 2014 | 485 | 0.080 |
Why?
| | Risk Assessment | 1 | 2019 | 3671 | 0.080 |
Why?
| | Risk Factors | 2 | 2020 | 10779 | 0.070 |
Why?
| | Antibodies, Viral | 2 | 2025 | 672 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5408 | 0.070 |
Why?
| | Animals | 3 | 2019 | 38058 | 0.070 |
Why?
| | Young Adult | 4 | 2019 | 14105 | 0.060 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1795 | 0.060 |
Why?
| | San Francisco | 1 | 2026 | 60 | 0.060 |
Why?
| | California | 2 | 2019 | 475 | 0.060 |
Why?
| | Scotland | 1 | 2025 | 23 | 0.060 |
Why?
| | Republic of Korea | 1 | 2025 | 42 | 0.060 |
Why?
| | Models, Biological | 2 | 2025 | 1821 | 0.060 |
Why?
| | Quality of Life | 1 | 2018 | 3185 | 0.060 |
Why?
| | Enterobacteriaceae | 1 | 2025 | 43 | 0.060 |
Why?
| | Immunoglobulin G | 2 | 2019 | 893 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2026 | 182 | 0.050 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2024 | 47 | 0.050 |
Why?
| | Cluster Analysis | 2 | 2016 | 521 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2730 | 0.050 |
Why?
| | Pregnancy | 1 | 2016 | 7190 | 0.050 |
Why?
| | Administration, Oral | 1 | 2025 | 847 | 0.050 |
Why?
| | Academic Medical Centers | 1 | 2026 | 547 | 0.050 |
Why?
| | Computational Biology | 2 | 2019 | 680 | 0.050 |
Why?
| | Adenoviridae | 1 | 2023 | 199 | 0.040 |
Why?
| | Immunologic Surveillance | 1 | 2022 | 25 | 0.040 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2024 | 248 | 0.040 |
Why?
| | Phylogeny | 2 | 2016 | 1016 | 0.040 |
Why?
| | Spatio-Temporal Analysis | 1 | 2021 | 39 | 0.040 |
Why?
| | Africa, Western | 1 | 2020 | 21 | 0.040 |
Why?
| | Living Donors | 1 | 2023 | 280 | 0.040 |
Why?
| | Technology | 1 | 2021 | 95 | 0.040 |
Why?
| | Child, Hospitalized | 1 | 2020 | 54 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2020 | 134 | 0.040 |
Why?
| | Consciousness Disorders | 1 | 2019 | 23 | 0.040 |
Why?
| | Picornaviridae | 1 | 2019 | 18 | 0.040 |
Why?
| | Encephalomyelitis, Acute Disseminated | 1 | 2019 | 11 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 348 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2947 | 0.030 |
Why?
| | Global Health | 1 | 2020 | 401 | 0.030 |
Why?
| | Neural Conduction | 1 | 2017 | 92 | 0.030 |
Why?
| | Atrophy | 1 | 2017 | 201 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 442 | 0.030 |
Why?
| | Sequence Homology | 1 | 2016 | 43 | 0.030 |
Why?
| | Health Information Systems | 1 | 2016 | 16 | 0.030 |
Why?
| | Open Reading Frames | 1 | 2016 | 132 | 0.030 |
Why?
| | Guatemala | 1 | 2017 | 345 | 0.030 |
Why?
| | Aftercare | 1 | 2017 | 223 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 769 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2023 | 1173 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 688 | 0.030 |
Why?
| | Genome, Viral | 1 | 2016 | 218 | 0.030 |
Why?
| | DNA, Viral | 1 | 2016 | 358 | 0.030 |
Why?
| | Brain Stem | 1 | 2014 | 95 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2016 | 285 | 0.030 |
Why?
| | Cost of Illness | 1 | 2016 | 321 | 0.030 |
Why?
| | Length of Stay | 1 | 2019 | 1337 | 0.020 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 488 | 0.020 |
Why?
| | Incidence | 1 | 2019 | 2879 | 0.020 |
Why?
| | Survival Rate | 1 | 2017 | 2089 | 0.020 |
Why?
| | Middle Aged | 3 | 2019 | 35875 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2117 | 0.020 |
Why?
| | Autoantibodies | 1 | 2019 | 1501 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3409 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4282 | 0.020 |
Why?
| | Critical Illness | 1 | 2016 | 891 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2925 | 0.020 |
Why?
| | Aged | 2 | 2019 | 25913 | 0.020 |
Why?
|
|
Messacar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|